John Parkinson is the assistant managing editor for Contagion. Prior to joining MJH Life Sciences in 2020, he has covered a variety of fields and markets including diabetes, oncology, ophthalmology, IT, travel, and local news. You can email him at jparkinson@mjhlifesciences.com.
This Week's News In Infectious Disease
August 20th 2023This week: the FDA accepts NDA for investigational antibiotic; mRNA COVID-19 vaccines update protections; counseling families on nirsevimab; and how antibiotic actions on gut microbes of patients might affect the microbiome of housemates.
Read More
Counseling Families on Nirsevimab
August 17th 2023With the FDA approval of nirsevimab-alip (Beyfortus), which is indicated for prevention of respiratory syncytial virus (RSV) in infants, clinicians will need to have important conversations with families around this monoclonal antibody, beginning this fall.
Read More
Long-Acting HIV Injectable Preferable to Daily Oral Regimen
July 24th 2023A new study being presented at the ongoing IAS conference showed that people with HIV found the injectable therapy, Cabotegravir plus long-acting Rilpivirine (Cabenuva) is more conducive to today’s lifestyles, reduced stigma, and improved adherence.
Read More
Almost Zero Risk of Sexually Transmitting HIV From People on ART with Low Levels of Virus
July 23rd 2023New study demonstrates benefit of adhering to treatment regimen and also calls for simplifying viral testing in other parts of the world where updated panels technology may not be available.
Read More
This Week's Top Five Infectious Disease Stories
July 22nd 2023Coverage this week included how COVID-19 vaccines in patients with cancer fared; analysis of non-COVID-19 adult vaccines; a company is developing a platform to enable engineering of the first recombinant human polyclonal antibody therapies with the goal of creating a functional cure for hepatitis b; and how a hospital modified testing for C difficile.
Read More
Investigational C diff Antibody Takes Novel Mechanism of Action Approach
July 14th 2023Lumen Bioscience's C diff therapy, LMN-201, combines four therapeutic proteins that act synergistically to neutralize both the C difficile bacterium and the toxin that causes its virulence directly in the patient’s gastrointestinal tract.
Read More